TY -的AU -拉赫曼博士Obaidur盟——Yamaji Noyuri盟——Nagamatsu Yasuko盟,Ota Erika PY - 2022 DA - 2022/4/22 TI -移动医疗干预措施对提高产前检查和熟练的分娩护理在低收入和中等收入国家:系统回顾和荟萃分析乔- J地中海互联网Res SP - e34061六世24 - 4 KW -移动健康KW - ANC KW -熟练的分娩护理KW - LMICs千瓦的系统回顾和荟萃分析AB -背景:产前保健和熟练分娩护理等基本孕产妇服务覆盖面不广，是低收入和中等收入国家孕产妇和婴儿死亡率较高的原因。尽管移动保健(mHealth)干预措施有可能改善资源有限环境下的服务利用率，但其有效性尚不清楚。目的:本综述旨在总结移动健康干预措施对提高低收入中国家孕妇ANC就诊、分娩时熟练助产和设施分娩的影响。方法:对9个电子数据库及其他资源进行综合检索，检索时间为建库至2020年10月。我们纳入了个体随机对照试验和聚类随机对照试验，以评估移动健康干预措施在改善中低收入国家健康孕妇围产期保健利用方面的有效性。我们进行了随机效应荟萃分析，并使用95% ci的风险比(RRs)估计合并效应大小。此外，2名审稿人使用Cochrane偏倚风险工具独立评估纳入研究的偏倚风险，使用推荐、评估、发展和评价分级法独立评估证据的确定性。结果:共纳入9项研究(10篇)，随机纳入10,348例孕妇(n=6254，干预组60.44%;N =4094，对照组为39.56%)纳入本合成。 The pooled estimates showed a positive effect of mHealth interventions on improving 4 or more ANC visit utilizations among pregnant women in LMICs, irrespective of the direction of interventions (1-way communications: RR 2.14, 95% CI 1.76-2.60, I2=36%, 2 studies, moderate certainty; 2-way communications: RR 1.17, 95% CI 1.08-1.27, I2=59%, 3 studies, low certainty). Only 2-way mHealth interventions were effective in improving the use of skilled birth attendance during delivery (RR 1.23, 95% CI 1.14-1.33, I2=0%, 2 studies, moderate certainty), but the effects were unclear for 1-way mHealth interventions (RR 1.04, 95% CI 0.97-1.10, I2=73%, 3 studies, very low certainty) when compared with standard care. For facility delivery, the interventions were effective in settings where fewer pregnant women used facility delivery (RR 1.68, 95% CI 1.30-2.19, I2=36%, 2 studies, moderate certainty); however, the effects were unclear in settings where most pregnant women already used facility delivery (RR 1.01, 95% CI 0.97-1.04, I2=0%, 1 study, low certainty). Conclusions: mHealth interventions may contribute to improving ANC and skilled delivery care utilization among pregnant women in LMICs. However, more studies are required to improve their reproducibility and efficiency or strengthen the evidence of different forms of mHealth interventions because of the considerable heterogeneity observed in the meta-analyses. Trial Registration: PROSPERO CRD42020210813; https://tinyurl.com/2n7ny9a7 SN - 1438-8871 UR - //www.mybigtv.com/2022/4/e34061 UR - https://doi.org/10.2196/34061 UR - http://www.ncbi.nlm.nih.gov/pubmed/35451987 DO - 10.2196/34061 ID - info:doi/10.2196/34061 ER -